AIM ImmunoTech Inc(AIM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 2 at 5:55 PM ET (Korea 11/3 07:55)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.84 | Insider Own | 0.67% | Shs Outstand | 39.9M | Perf Week | -1.89% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 37.21% | Insider Trans | 89.04% | Shs Float | 39.6M | Perf Month | -10.72% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.14 | Inst Own | 2.88% | Short Float | 2.72% | Perf Quarter | -38.9% |
| Income | -0.01B | P/S | 64.07 | EPS this Y | 90.02% | Inst Trans | 3.1% | Short Ratio | 0.23 | Perf Half Y | -68.89% |
| Sales | 0.00B | P/B | 0.6 | EPS next 5Y | 58.64% | ROA | -169.28% | Short Interest | 1.08M | Perf YTD | -85.76% |
| Book/sh | 0.27 | P/C | 0.64 | EPS past 3/5Y | 40.27% 28.21% | ROE | -2382.3% | 52W High | -92.79% ($2.23) | Perf Year | -92.34% |
| Cash/sh | 0.25 | P/FCF | - | Sales past 3/5Y | -14.54% -11.6% | ROIC | -183.3% | 52W Low | 6.92% ($0.15) | Perf 3Y | -99.69% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 84.62% | Gross Margin | -726.32% | Volatility(W/M) | 5.39% 5.83% | Perf 5Y | -99.91% |
| Dividend TTM | - | EV/Sales | 3.67 | Sales Y/Y TTM | -21.49% | Oper. Margin | -11148.42% | ATR (14) | 0.01 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 2.11 | EPS Q/Q | 93.98% | Profit Margin | -15021.05% | RSI (14) | 39.58 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.11 | Sales Q/Q | 4% | SMA20 | -4.35% ($0.17) | Beta | 1.32 | Target Price | $4.25 |
| Payout | - | Debt/Eq | 0.51 | Earnings | 2026/8/10 | SMA50 | -18.74% ($0.2) | Rel Volume | 0.07 | Prev Close | $0.15 |
| Employees | 19 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -152.94% - | SMA200 | -66.8% ($0.48) | Avg Volume(3M) | 4.63M | Price | $0.16 |
| IPO | 1996/7/15 | Option/Short | No/Yes | Trades | 456 | Volume | 305,159 | Change | 4.01% |
💉 This is a small U.S. biotech developing immuno-modulating anti-cancer and antiviral therapeutics. Its lead pipeline candidate is Ampligen (rintatolimod), aimed at pancreatic cancer, currently in a Phase 2 clinical trial in combination with AstraZeneca's Imfinzi.
Over the past 1 year, on the lower side
93% below its 1-year high.
Traded less than usual. That is 7% of its average volume.
AIM has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +90.0% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $6,407. Peers typically go for $946.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.9%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.9%.
Tap to view numbers
It ranks #530 of 597 in the industry
Based on market cap of $6M.
EVGN#527 Evogene Ltd $7M PER - 
ENVB#528 Enveric Biosciences Inc $6M PER - 
CNSP#529 Cns Pharmaceuticals Inc $6M PER - AIM#530 AIM ImmunoTech Inc $6M PER - 
TCRT#531 Alaunos Therapeutics Inc $6M PER - 
FAQ
What kind of company is AIM?
AIM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AIM?
The market cap of AIM is approximately $6M, ranking 5,554 within its sector.
What is the 52-week high and low for AIM?
AIM has recorded a 52-week high of $2.23 and a low of $0.15.
